Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Not Confirmed
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Industry Trade Show
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions
15 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/beacon-therapeutics-announces-positive-24-month-data-from-phase-2-skyline-trial-of-agtc-501-in-patients-with-x-linked-retinitis-pigmentosa-302275688.html
19 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/beacon-therapeutics-presents-36-month-interim-results-from-phase-i2-horizon-trial-of-agtc-501-in-patients-with-xlrp-302252375.html
24 Jul 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/07/24/2917905/0/en/Beacon-Biosignals-Announces-Strategic-Collaboration-with-Skye-Bioscience-to-Integrate-Sleep-Quality-and-Sleep-Apnea-Endpoints-in-CBEYOND-Phase-2-Trial-of-Nimacimab-for-Obesity.html
03 Jul 2024
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/beacon-attracts-170m-series-b-push-eye-disease-gene-therapy-through-late-stage-trial
17 Jun 2024
// PHARMACEUTICAL TECHNOLOGY
https://www.pharmaceutical-technology.com/analyst-comment/beacon-therapeutics-agtc-501-vista/
06 May 2024
// Phil Taylor PHARMAPHORUM
https://pharmaphorum.com/news/eyedna-plans-pivotal-trial-retinitis-pigmentosa-therapy
Details:
AGTC-501 (laruparetigene zovaparvovec) is an XLRP GTPase regulator cell & gene therapy candidate, which is being evauated for the treatment of patients suffering from X-linked retinitis Pigmentosa.
Lead Product(s): Laruparetigene Zovaparvovec
Therapeutic Area: Genetic Disease Brand Name: AGTC-501
Study Phase: Phase IIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2024
Lead Product(s) : Laruparetigene Zovaparvovec
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Beacon Shows Positive 24-Month Data from AGTC-501 Phase 2 in XLRP
Details : AGTC-501 (laruparetigene zovaparvovec) is an XLRP GTPase regulator cell & gene therapy candidate, which is being evauated for the treatment of patients suffering from X-linked retinitis Pigmentosa.
Brand Name : AGTC-501
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 15, 2024
Details:
AGTC-501 (laruparetigene zovaparvovec) is an XLRP GTPase regulator cell & gene therapy candidate, which is being evauated for the treatment of patients suffering from X-linked retinitis Pigmentosa.
Lead Product(s): Laruparetigene Zovaparvovec
Therapeutic Area: Genetic Disease Brand Name: AGTC-501
Study Phase: Phase II/ Phase IIIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2024
Lead Product(s) : Laruparetigene Zovaparvovec
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Beacon Presents 36-Month Results from Phase I/2 HORIZON Trial of AGTC-501
Details : AGTC-501 (laruparetigene zovaparvovec) is an XLRP GTPase regulator cell & gene therapy candidate, which is being evauated for the treatment of patients suffering from X-linked retinitis Pigmentosa.
Brand Name : AGTC-501
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
September 19, 2024
Details:
Under the terms of the agreement, Beacon will be responsible for the development and commercialization of AAV204 capsid for potential use for the treatment of retinal diseases.
Lead Product(s): AAV204
Therapeutic Area: Ophthalmology Brand Name: AAV204
Study Phase: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Abeona Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 11, 2024
Lead Product(s) : AAV204
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Recipient : Abeona Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Abeona and Beacon Sign Non-Exclusive Deal for AAV204 Capsid for Ophthalmology
Details : Under the terms of the agreement, Beacon will be responsible for the development and commercialization of AAV204 capsid for potential use for the treatment of retinal diseases.
Brand Name : AAV204
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 11, 2024
Details:
The funds will support the continued clinical development of Beacon's lead asset, AGTC-501 for the treatment of patients suffering from X-linked retinitis Pigmentosa.
Lead Product(s): Laruparetigene Zovaparvovec
Therapeutic Area: Genetic Disease Brand Name: AGTC-501
Study Phase: Phase IIProduct Type: Cell and Gene therapy
Sponsor: TCGX
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Series B Financing July 03, 2024
Lead Product(s) : Laruparetigene Zovaparvovec
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : TCGX
Deal Size : Undisclosed
Deal Type : Series B Financing
Beacon attracts $170M series B to push eye disease gene therapy through late-stage trial
Details : The funds will support the continued clinical development of Beacon's lead asset, AGTC-501 for the treatment of patients suffering from X-linked retinitis Pigmentosa.
Brand Name : AGTC-501
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 03, 2024
Details:
The financing aims to advance the clinical development of Beacon's lead product AGTC-501 (laruparetigene zovaparvovec), which is being evaluated in the treatment of X-Linked Retinitis Pigmentosa.
Lead Product(s): Laruparetigene Zovaparvovec
Therapeutic Area: Genetic Disease Brand Name: AGTC-501
Study Phase: Phase II/ Phase IIIProduct Type: Cell and Gene therapy
Sponsor: TCGX
Deal Size: $170.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing July 03, 2024
Lead Product(s) : Laruparetigene Zovaparvovec
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : TCGX
Deal Size : $170.0 million
Deal Type : Series B Financing
Beacon attracts $170M series B to push eye disease gene therapy through late-stage trial
Details : The financing aims to advance the clinical development of Beacon's lead product AGTC-501 (laruparetigene zovaparvovec), which is being evaluated in the treatment of X-Linked Retinitis Pigmentosa.
Brand Name : AGTC-501
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 03, 2024
Details:
AGTC-501 (laruparetigene zovaparvovec) is an XLRP GTPase regulator cell & gene therapy candidate, which is being evauated for the treatment of patients suffering from X-linked retinitis Pigmentosa.
Lead Product(s): Laruparetigene Zovaparvovec
Therapeutic Area: Genetic Disease Brand Name: AGTC-501
Study Phase: Phase II/ Phase IIIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2024
Lead Product(s) : Laruparetigene Zovaparvovec
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Beacon Therapeutics treats first patient with AGTC-501 in pivotal VISTA trial
Details : AGTC-501 (laruparetigene zovaparvovec) is an XLRP GTPase regulator cell & gene therapy candidate, which is being evauated for the treatment of patients suffering from X-linked retinitis Pigmentosa.
Brand Name : AGTC-501
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 17, 2024
Details:
The financing will fund Beacon's lead asset, AGTC-501, a gene therapy program in Phase II trials for the treatment of X-linked retinitis pigmentosa. AGTC-501 expresses the full length RPGR protein, thereby addressing the full complement of photoreceptor damage caused by XLRP.
Lead Product(s): Recombinant Adeno-associated Virus Vector
Therapeutic Area: Genetic Disease Brand Name: AGTC-501
Study Phase: Phase II/ Phase IIIProduct Type: Cell and Gene therapy
Sponsor: Syncona Limited
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 12, 2023
Lead Product(s) : Recombinant Adeno-associated Virus Vector
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Syncona Limited
Deal Size : $120.0 million
Deal Type : Financing
Beacon Therapeutics Launches with £96 Million ($120 million) to Develop a New Generation of Gene ...
Details : The financing will fund Beacon's lead asset, AGTC-501, a gene therapy program in Phase II trials for the treatment of X-linked retinitis pigmentosa. AGTC-501 expresses the full length RPGR protein, thereby addressing the full complement of photoreceptor ...
Brand Name : AGTC-501
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 12, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?